[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382769":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":36,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":7,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":43,"conditions":50,"keywords":53,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",null,[9],{"name":10,"affiliation":5,"role":11},"Yanyan Liu, M.D. Ph.D","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+8613818176375","yyliu@zzu.edu.cn",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Henan Cancer Hospital\u002FThe affiliated Cancer Hospital of ZhengZhou university","RECRUITING","Zhengzhou","Henan","China","CN",{"type":26,"coordinates":27},"Point",[28,29],113.64861,34.75778,{"lat":29,"lon":28},[32,34],{"name":10,"role":14,"phone":33,"phoneExt":7,"email":16},"+8613838176375",{"name":10,"role":35,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":35,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Yanyan Liu","Director","100382769","correlation-between-driver-gene-abnormalities-and-clinicopathological-characteristics-and-disease-prognosis-in-lymphoma-100382769",false,"NCT04263935","Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma","Inclusion Criteria:\n\n1. Diagnosed as lymphoma (according to WHO 2017 classification criteria)\n2. Life expectancy no less than 3 months\n3. Agreeing to sign the written informed consents\n\nExclusion Criteria:\n\n1. Other malignant tumor history or active malignant tumor need be treated\n2. Researchers determine unsuited to participate in this trial","ALL",{"count":47,"type":48},200,"ESTIMATED","OBSERVATIONAL",[51,52],"Lymphoma","Gene Abnormality",[51,54,55],"Driver Gene Abnormalities","Disease Prognosis","2025-04-18",{"date":58,"type":59},"2025-04-23","ACTUAL",{"date":61,"type":59},"2019-01-03",{"date":63,"type":48},"2025-12-31",{"name":5,"class":6},1]